Skip to content

Home
IOncology
Infectious Desease Frontier
IHepatology
Hematology Frontier
Conference topics
Experts Interviews
Informations
Live Broadcasting
Logout

Connecting Medical Expertise through Media

Search for:

Home
IOncology
Infectious Disease Frontier
International Hepatology
Hematology Frontier
Conference topics
Experts’ Interviews
Informations

Home
IOncology
Infectious Disease Frontier
International Hepatology
Hematology Frontier
Conference topics
Experts’ Interviews
Informations

Search for:

# AASLD 2023

Home » # AASLD 2023 » Page 2

Current treatment status and challenges for intermediate and advanced stage HCC

Current treatment status and challenges for intermediate and advanced stage HCC

Posted by

By Xiaorong JI 2024.02.18

<Hepatology Digest>: What is the efficacy of current treatment strategies for intermediate and advanced stage HCC, and what are the challenges and limitations associated with them?

The mechanism of tumor microenvironment affecting the occurrence and development of HCC

The mechanism of tumor microenvironment affecting the occurrence and development of HCC

Posted by

By Xiaorong JI 2024.02.18

<Hepatology Digest>: How does the tumor immune microenvironment affect the efficacy of precision HCC therapy?

The worldwide prevalence trend of MASLD

The worldwide prevalence trend of MASLD

Posted by

By Xiaorong JI 2024.02.18

<Hepatology Digest>: What is the prevalence trend of MASLD globally? Are there specific regions or populations that are more affected and why?

What is the association between the microbiome and autoimmune liver diseases?

What is the association between the microbiome and autoimmune liver diseases?

Posted by

By Xiaorong JI 2024.02.18

<Hepatology Digest>: What role does microbiomics play in the pathogenesis of autoimmune liver diseases? What current research findings have revealed the association between the microbiome and autoimmune liver diseases?

The U.S. Experience in HCV Screening, Linkage, and Treatment

The U.S. Experience in HCV Screening, Linkage, and Treatment

Posted by

By Xiaorong JI 2024.01.31

Pinnacle Conversation | Advancements in the Diagnosis and Treatment of Metabolism-Related Fatty Liver Disease: Discussing New Developments, Sharing Experiences from Singapore and the United States, and Addressing Global Progress

Pinnacle Conversation | Advancements in the Diagnosis and Treatment of Metabolism-Related Fatty Liver Disease: Discussing New Developments, Sharing Experiences from Singapore and the United States, and Addressing Global Progress

Posted by

By Xiaorong JI 2024.01.31

Interview with AASLD President: A Resurgence of Vitality in the Field of Liver Disease, Highlights Galore at 2023 Annual Meeting

Interview with AASLD President: A Resurgence of Vitality in the Field of Liver Disease, Highlights Galore at 2023 Annual Meeting

Posted by

By Xiaorong JI 2024.01.31

Four New Insights into the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Four New Insights into the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Posted by

By Xiaorong JI 2024.01.31

Progress in the Treatment of Intermediate and Advanced HCC, Highlighting the Value of Systemic Therapy

Progress in the Treatment of Intermediate and Advanced HCC, Highlighting the Value of Systemic Therapy

Posted by

By Xiaorong JI 2024.01.31

The main mechanisms and development prospects of HCC combination therapy

The main mechanisms and development prospects of HCC combination therapy

Posted by

By Xiaorong JI 2024.01.31

Posts pagination

Previous page 1 2 3 Next page

Recent Posts

EBMT 2026 China Voice | Dr. Yishan Ye: Rethinking Donor Selection — Haploidentical Transplantation May Be the Optimal Choice for MRD-Positive AML
EBMT 2026 China Voice | Professor Xiaojun Huang: Haploidentical Hematopoietic Stem Cell Transplantation for Rare Diseases — Practice and Insights from the Beijing Protocol
EBMT 2026 China Voice | Professor Jia Wei: A Powerful Combination Strategy Reshaping the Tumor Microenvironment and Opening a New Era of Durable Benefit in CAR-T Therapy
EBMT 2026 China Voice | Professor Yuqian Sun: A New Strategy for Donor Selection in Elderly Haploidentical Transplantation — Younger Donors Are Better
ASCO GU Expert Insights | Professor Scott T. Tagawa: Transforming Prostate Cancer Care and the Future of Precision Therapy

Recent Comments

Archives

Categories

Artificial intelligence
Hematology Frontier
Infectious Disease Frontier
International Hepatology
IOncology
Live broadcasting
Uncategorized
UroStream

LinkedIn
Twitter
Mail

Related Media:

Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
Paris, France